INTRAVACC B.V.

INTRAVACC B.V. specializes in the design and development of novel vaccine platforms targeting emerging infectious threats, with a focus on innovative delivery systems and immunomodulatory adjuvants. Their technical expertise lies in outer membrane vesicle engineering, sustained-release microsphere formulation, and inactivated whole-virus vaccine development, bridging preclinical research with early-phase clinical translation. The contractor demonstrates deep proficiency in recombinant protein expression, viral vector characterization, and cytokine-enhanced immune priming—particularly through the use of interleukin-12 as a Th1-skewing adjuvant. Their work emphasizes rational vaccine design grounded in structural immunology and targeted mucosal or systemic delivery, setting them apart in the niche of non-traditional, mechanism-driven vaccine candidates for under-served pathogens. The contractor has consistently partnered with the Department of Health and Human Services, delivering research and development services focused on vaccine candidates for high-priority public health threats, including Neisseria gonorrhoeae and enterovirus D68. Their engagements reflect a pattern of sustained collaboration on early-stage vaccine platforms, from antigen selection through Phase I clinical readiness, indicating a trusted role in HHS’s biodefense and emerging pathogen preparedness initiatives. INTRAVACC B.V. operates primarily within NAICS 541715, conducting applied research in life sciences with an emphasis on immunological intervention strategies. Their market positioning centers on advanced vaccine innovation outside conventional biotechnology domains, targeting gaps in bacterial and viral vaccine development where traditional approaches have failed. This places them in a specialized segment of the federal biomedical R&D ecosystem focused on next-generation immunotherapeutics. As a 2L entity based in Bilthoven, the company maintains a lean, research-driven structure without formal government certifications. Their geographic presence is anchored in Europe, yet their contract activity is fully aligned with U.S. federal health priorities, positioning them as an international contributor to U.S. public health R&D initiatives.